Filed Pursuant to Rule 424(b)(3)
Registration Nos. 333-259797 and 333-257440
PROSPECTUS SUPPLEMENT NO. 14
(to Prospectus
dated October 7, 2021)
Rocket Lab USA, Inc.
This prospectus supplement is being filed to update and supplement the information contained in the combined prospectus dated October 7, 2021 (as
supplemented or amended from time to time, the Prospectus), which forms a part of our Registration Statements on Form S-1 (Registration Nos. 333-259797 and 333-257440). This prospectus supplement is being filed to update and supplement the information included or incorporated by reference in the Prospectus with the information contained in our Current Report on Form 8-K, filed with the Securities and Exchange Commission (the SEC) on April 15, 2022 (the Form 8-K). Accordingly, we have
attached the Form 8-K to this prospectus supplement.
This prospectus supplement updates and supplements
the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction
with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.
Our common stock is listed on the Nasdaq Capital Market under the symbol RKLB. On April 14, 2022, the last reported sales price of our
common stock was $8.42 per share.
We are an emerging growth company as defined in Section 2(a) of the Securities Act of 1933, as amended, and, as such, have elected to
comply with certain reduced disclosure and regulatory requirements.
Investing in our securities
involves risks. See the section entitled Risk Factors beginning on page 9 of the Prospectus.
Neither the SEC nor any state securities
commission has approved or disapproved of the securities to be issued or sold under the Prospectus or determined if the Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus supplement is April 15, 2022